Member Info for inanaco

you see the one area that you have no considered .....

as well all know the majority now of Big Pharma deals are based around third party projects .. like scancell

Scancell has not taken a product developed by others like Val or MTFB ..

the products are developed in house either by the university or directly by scancell but over sight is still done all the way through by lindy

so scancell are at the top of the game to evaluate the science data as its progresses after all they are the Inventor, so nobody is effectively above them in knowledge of the product ...

so scancell also then knows the risk of taking each product through the clinic and the value or uplift that the data could lead to on milestones ... so in effect can control the value generated by not asking to higher price upfront because it knows the chance of success in trial ... and can quantify the risk of success

Think about it

Ruck ... if its common sense why are you not buying ....

Crumbs has common sense and is ....

Crumbs you have only considered "upfront" ..... what happens to milestones which are linked to results

continued ran of of space

neither has failed so "synergy must exist" ....

no its not ......... standard supply and demand = £5

the world now wants to buy it ............

so the Moaning on here and the "Frustrations" targeting the BOD as an area that needs to be improved actually are unfounded in that the Company itself has stated ..........

The cancer immunotherapy market is one of the most rapidly growing markets within the biopharmaceutical industry, estimated to be worth USD100 billion by the year 2022. Immunotherapies are being evaluated in most cancer indications and their unrivalled efficacy and relatively low toxicity profile compared to chemotherapy is already leading to paradigm shifts in the treatment of many cancers. However, tumours often successfully evade the body’s own natural defence mechanism, the immune system, and not all patients are able to respond to checkpoint inhibitor-based immunotherapies. Therapeutic vaccines therefore have the potential to improve the proportion of patients who are able to benefit by initiating immune responses that convert unresponsive tumours, or so-called “cold” tumours, into “hot” ones.

The commercial potential of Scancell’s products will be defined by clinical data, either as monotherapies or in combination with checkpoint inhibitors, designed to provide increased and durable responses in patients without compromising safety and to address the unmet needs in hard to treat cancers. Scancell’s three technology platforms, ImmunoBody®, Moditope® and AvidiMab™, each offers a unique approach to cancer therapy to address all of these criteria.

""" The commercial potential of Scancell’s products will be defined by clinical data"""

So why are you buying shares ? why did you buy shares ?

well you already have fantastic clinical data from SCIB1 ............. but because its market has changed you have to value the synergy not the mono therapy ... back to trials again ......... back to the mission statement

Do you really think if we get the expected efficacy of 55% in melanoma that you will be able to buy at 6p ...... ???

which then gives an indication of the potential of Scib2 which surely must add to the potential ???

so the lead product carries the platform ......... Immunobody

Moditope is in another class because we own the "targets" if we get efficacy then the product creates a market size that most cannot imagine ...

it becomes dexamethasone

its the old story nobody knows which deal and when will drop ..................... all those giving it the big one maybe correct we might not get a deal this week ............ we may need to raise on the market ......

but what you have to consider now our portfolio is now so wide in its approach we have multiple attempts to get that one "bit of data" that changes the Scancell landscape for ever ...

so its now basic maths ............ if you feel the science is good enough, how many are you prepared to hold because trying to buy after you have the data is not the same as buying before ...

which is why i keep saying which product has failed

SCIB1 or Keytruda ....

Neither s

Marketing ................

First Identify your market ............. research the competition is the obvious main area, but its clouded because in this industry trials give you a window on what it might be like in the future ........... which is why Crumbs Wild etc post links of other deals and other trials.

The market is identified in two areas .......

Can you out perform the current "standard of Care"

or Is this a new market as no "standard of care exists " so you create a market !! so you cannot predict market size for Covid for instance as no sales of drugs have occurred that you can say yes the market is worth X ...............so dexamethasone will go into short supply and its the manufactures of this out of patent drug will do really well .. They do not need to market the product at all ........ Being the new ""standard of care"" has done wonders for them

So SCIB1 as an adjuvant treatment back in 2012 had no competition its marketing to the Big Pharma fell over not because the vaccine was poor but the industry kept getting its fingers burnt with poor "Platforms"

The market then changed with the Check points getting in on the act so all of a sudden the industry went berserk for Check points with the Market size being "created" by the lead players Keytruda and Opdivo as prior to that no market existed but now because it does ,you can approach this market with more confidence that sales will follow if you can out perform this new "standard of care"

as Checkpoints are synergistic with Vaccines .. if you have a good vaccine it will work with a checkpoint .. this has been proven many times now, and of particular interest is Genexine trial with Merck

Avidmab ........ No market exists yet .. because its a trial blazing product
Moditope ...... No Market exists yet as its also a trial blazing product

but what we do know if something works the sales go from zero to hero very very quickly ........yet no advertising is seen on TV ???

So you guys are looking for Visible presence ......... but the industry works from behind closed doors ...via peer revue and presentations of results etc, and this is what we cannot see.

What Scancell have said they prefer to do deals after trials not before, obvious reasons, its the most easiest point to start putting value to what you have created because you have "efficacy" data and "safety data"

so ........ not sure how marketing can be improved and IMHO closing deals in this scenario is not about personalities its about Data

learn to read

ATB

""" You buying a few bobs worth of another pi does not bring money to Scancell.""

agree, but then you not buying at all has no effect at all ......... ie zero

I have convinced myself that my excess cash put into scancell is about as safe as i can make it by studying the science

leaving me "Not Frustrated"

i have no idea how you will solve your issues as you have absolutely no control over how Scancell proceeds

and having a song and dance on here .... will not resolve it either

Funny Diggles thought it was cheap as well and bought 80m ... do love this minute small trades

your last buy at 10p ... ? how is that going for you, apart from give you the "frustrations" still if your healthy and wealthy time should be of little concern

Tick Tock

message we have got ... "Ruck"

The SP is cheap which is why we keep topping up ...........

why don't you ?

another point Ivy .... HIV does not Kill you ........ but it causes

acquired immunodeficiency syndrome which does ..

""" It is only a chronic condition due to the effectiveness of current treatments at the time I would call it pretty acute as fir most people it was a death sentence."""

sorry to Hear that ... well i hope your Chronic Flu gives way to a Happy Ivy ...

Love Ivy description

No one is saying Viral Vax are harder to develop than Cancer Vax but to pretend you knock them up in the back kitchen is ludicrous.

who suggested they are built in a kitchen ?

why does Bermuda support such ridiculous posters .. ?

""""Has there been a Vax developed for HIV hardly and that research has being going on fornearly 40 years ? """"

do you understand why ? HIV mutates so fast its evades the immune system constantly ..............

its also a chronic condition ........... i suppose you have the Chronic Flu .. always down !

yes and you still fail to understand that its all about the platform ............

nothing to do with the target .........

"""""Many of the deaths are where people have successfully killed the virus but their immune response has gone berserk- cytokine attack.""""

""successfully killed""

would love to see the evidence

so in theory ......... if you subsequently got infected and went on to develop CRS

the vaccine did absolutely nothing and had failed .. certainly not caused ...

Ruck .......... CRS occurs because your immune system has kicked and gone into over drive in 10 to 14 days after being infected ...

the idea of a vaccine is the immune system has already kicked in before you get infected .... thus the virus never gets a real foot hold

"""" Sorry WTP but I don't think you can compare Oxford's vaccine with Scancell's - there's a gulf between them in development terms. """"

Bermudashorts

Posted in: SCLP

Posts: 10,665

Price: 6.55

No Opinion

RE: UK appoints Kate Bingham as chair of its Covid-19 vaccine taskforce18 May 2020 21:08
Sorry WTP but I don't think you can compare Oxford's vaccine with Scancell's - there's a gulf between them in development terms. Have seen lots of comments regarding ChAdOx1 on the bb today and think some balance is needed.

You may be right and nepotism may be at play here. On the other hand, if you were a scientist advising the Government on the best vaccine candidates to fund, the following might be valid reasons to choose ChAdOx1 .

1) Oxford had already developed ChAdOx1 for another coronavirus (MERS)
2) It had already been through Phase I trials for MERS, had shown that it was safe and shown encouraging signs of efficacy
3) Based on that clinical trial it had been taken forward into clincial trials in Saudi where MERS still rumbles on
4) The Oxford team started working on converting ChAdOx1 for COVID-19 in early January, even before the Chinese revealed that there was human to human transmission
5) It's not self-replicating making it safer to give to children, the elderly or those with pre-existing conditions

The speed with which the Oxford team have moved this vaccine into the clinic is astonishing and a fantastic achievement. We don't know whether the trial will be a success, partial success or outright fail but even today it's the only UK candidate in trials. I wonder what folks would have said if an existing coronavirus vaccine from one of the (if not the) top universities in the World was left on the shelf due to lack of funding?

this is Bermuda, Ivy and Ruck ... pushing this nonsense .... despite enormous evidence to the contrary

indeed .............. the new kids on the block MRNA ........ don't yet have an approved vaccine ...

https://horizon-magazine.eu/article/five-things-you-need-know-about-mrna-vaccines.html

and the Oxford group failed at trying to build a flu vaccine ...